256 related articles for article (PubMed ID: 20131232)
1. The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.
Jung H; Bobba R; Su J; Shariati-Sarabi Z; Gladman DD; Urowitz M; Lou W; Fortin PR
Arthritis Rheum; 2010 Mar; 62(3):863-8. PubMed ID: 20131232
[TBL] [Abstract][Full Text] [Related]
2. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.
Shinjo SK; Bonfá E; Wojdyla D; Borba EF; Ramirez LA; Scherbarth HR; Brenol JC; Chacón-Diaz R; Neira OJ; Berbotto GA; De La Torre IG; Acevedo-Vázquez EM; Massardo L; Barile-Fabris LA; Caeiro F; Silveira LH; Sato EI; Buliubasich S; Alarcón GS; Pons-Estel BA;
Arthritis Rheum; 2010 Mar; 62(3):855-62. PubMed ID: 20131238
[TBL] [Abstract][Full Text] [Related]
3. Factors associated with osteonecrosis in Thai lupus patients: a case control study.
Uea-areewongsa P; Chaiamnuay S; Narongroeknawin P; Asavatanabodee P
J Clin Rheumatol; 2009 Oct; 15(7):345-9. PubMed ID: 20009970
[TBL] [Abstract][Full Text] [Related]
4. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
[TBL] [Abstract][Full Text] [Related]
5. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
Sisó A; Ramos-Casals M; Bové A; Brito-Zerón P; Soria N; Muñoz S; Testi A; Plaza J; Sentís J; Coca A
Lupus; 2008 Apr; 17(4):281-8. PubMed ID: 18413408
[TBL] [Abstract][Full Text] [Related]
6. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus.
Akhavan PS; Su J; Lou W; Gladman DD; Urowitz MB; Fortin PR
J Rheumatol; 2013 Jun; 40(6):831-41. PubMed ID: 23588942
[TBL] [Abstract][Full Text] [Related]
7. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.
Tektonidou MG; Laskari K; Panagiotakos DB; Moutsopoulos HM
Arthritis Rheum; 2009 Jan; 61(1):29-36. PubMed ID: 19116963
[TBL] [Abstract][Full Text] [Related]
9. Risk for incident arterial or venous vascular events varies over the course of systemic lupus erythematosus.
Chang ER; Pineau CA; Bernatsky S; Neville C; Clarke AE; Fortin PR
J Rheumatol; 2006 Sep; 33(9):1780-4. PubMed ID: 16832849
[TBL] [Abstract][Full Text] [Related]
10. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
Parke A; West B
J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
[TBL] [Abstract][Full Text] [Related]
11. Antimalarial drugs, systemic lupus erythematosus and pregnancy.
Parke AL
J Rheumatol; 1988 Apr; 15(4):607-10. PubMed ID: 3397970
[TBL] [Abstract][Full Text] [Related]
12. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.
López P; Gómez J; Mozo L; Gutiérrez C; Suárez A
Arthritis Res Ther; 2006; 8(2):R42. PubMed ID: 16507146
[TBL] [Abstract][Full Text] [Related]
13. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE.
Wallace DJ; Linker-Israeli M; Metzger AL; Stecher VJ
Lupus; 1993 Feb; 2 Suppl 1():S13-5. PubMed ID: 8485565
[TBL] [Abstract][Full Text] [Related]
14. Thrombovascular events in systemic lupus erythematosus: comment on the article by Jung et al.
Wallace DJ
Arthritis Rheum; 2010 Sep; 62(9):2824; author reply 2824-5. PubMed ID: 20872599
[No Abstract] [Full Text] [Related]
15. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
Somers E; Magder LS; Petri M
J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study.
Bessant R; Duncan R; Ambler G; Swanton J; Isenberg DA; Gordon C; Rahman A
Arthritis Rheum; 2006 Dec; 55(6):892-9. PubMed ID: 17139666
[TBL] [Abstract][Full Text] [Related]
17. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study.
Cooper GS; Dooley MA; Treadwell EL; St Clair EW; Gilkeson GS
Arthritis Rheum; 2002 Jul; 46(7):1830-9. PubMed ID: 12124867
[TBL] [Abstract][Full Text] [Related]
18. A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus.
Svenungsson E; Gustafsson J; Leonard D; Sandling J; Gunnarsson I; Nordmark G; Jönsen A; Bengtsson AA; Sturfelt G; Rantapää-Dahlqvist S; Elvin K; Sundin U; Garnier S; Simard JF; Sigurdsson S; Padyukov L; Syvänen AC; Rönnblom L
Ann Rheum Dis; 2010 May; 69(5):834-40. PubMed ID: 19762360
[TBL] [Abstract][Full Text] [Related]
19. Thrombosis in systemic lupus erythematosus: risk and protection.
Burgos PI; Alarcón GS
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1541-9. PubMed ID: 19954316
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of risk factors that contribute to high prevalence of premature atherosclerosis in Chinese premenopausal systemic lupus erythematosus patients.
Zhang CY; Lu LJ; Li FH; Li HL; Gu YY; Chen SL; Bao CD
J Clin Rheumatol; 2009 Apr; 15(3):111-6. PubMed ID: 19300290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
